Login to Your Account



Firdapse cardiac safety study hits endpoint; LEMS data next

By Marie Powers
Staff Writer

Thursday, January 9, 2014
The first formal human cardiac safety study of Firdapse (amifampridine phosphate) met its pre-specified endpoint, demonstrating no effect on heart rate or cardiac depolarization when administered at and above therapeutic levels.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription